Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Rendu Biotechnology CoSHSE:688193 -1.52%61 EBITDA Margin % is 13.12% as of Mar. 2026, which is 1% below its 10-year median of 13.25. GuruFocus rates SHSE:688193 with a GF Score™ of 61/100 and a GF Value™ of ¥35.09 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Shanghai Rendu Biotechnology Co ranks better than 57.14% on this metric.
Shanghai Rendu Biotechnology Co (SHSE:688193) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Rendu Biotechnology Co EBITDA Margin % Related Terms
Shanghai Rendu Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rendu Biotechnology Co EBITDA Margin % Chart
SHSE:688193 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rendu Biotechnology Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Rendu Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rendu Biotechnology Co (SHSE:688193) has a EBITDA Margin % of 13.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Rendu Biotechnology Co and its competitors. This is near median its historical median of 13.25. According to the industry distribution chart, Shanghai Rendu Biotechnology Co ranks #87 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 42.9%.
Is Shanghai Rendu Biotechnology Co's EBITDA Margin % too high?
Shanghai Rendu Biotechnology Co's current EBITDA Margin % of 13.12% is near median its 10-year median of 13.25. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Shanghai Rendu Biotechnology Co's value of 13.12% is 162.4% above this industry median. Based on the distribution chart, Shanghai Rendu Biotechnology Co ranks #87 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shanghai Rendu Biotechnology Co has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rendu Biotechnology Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Rendu Biotechnology Co ranks #87 out of 203 companies for EBITDA Margin %. This puts Shanghai Rendu Biotechnology Co in the upper half of its industry. The industry median EBITDA Margin % is 5.00. Shanghai Rendu Biotechnology Co's value of 13.12% is 162.4% above this benchmark. While the company's 10-year median is 13.25 vs. the industry median of 5.00, Shanghai Rendu Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Rendu Biotechnology Co's current EBITDA Margin % of 13.12% is 162.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Rendu Biotechnology Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Rendu Biotechnology Co's current EBITDA Margin % is 13.12%, which is near median its own 10-year median of 13.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rendu Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co (SHSE:688193) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥35.09, compared to a current price of ¥41.41 — trading 18% above its estimated fair value. The current EBITDA Margin % is 13.12%, which is near median its 10-year median of 13.25 and 162.4% above the Medical Diagnostics & Research industry median of 5.00. Shanghai Rendu Biotechnology Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Rendu Biotechnology Co (SHSE:688193), the current EBITDA Margin % is 13.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rendu Biotechnology Co (SHSE:688193) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co stock appears to be overvalued.
The current stock price of ¥41.41 is trading 18% above its estimated GF Value™ of ¥35.09.
GuruFocus considers Shanghai Rendu Biotechnology Co to be Modestly Overvalued.
Key valuation signals for SHSE:688193:
EBITDA Margin %: 13.12% (near median its 10-year median of 13.25)
GF Value™: ¥35.09 vs. price of ¥41.41 (18% above fair value)
Industry Position: 162.4% above the Medical Diagnostics & Research median (#87 of 203)
No single metric tells the full story. See the SHSE:688193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rendu Biotechnology Co Business Description
Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.
61GF Score
Get the complete analysis for SHSE:688193
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688193 has been successfully added to your 
